• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Jan. 8, 2019

View Archived Issues

New year rings in return to big deals as M&A engine fires up

The analysis of biopharma dealmaking trends by Clarivate Analytics at last year's J.P. Morgan Healthcare Conference (JPM) suggested the industry would continue to evolve rapidly as targeted therapies reshuffled the oncology space and other broad therapeutic areas – especially neuroscience and anti-infectives – faced clinical and financial headwinds. The challenge going forward, concluded Laura Vitez, commercial insights manager with Cortellis, and Jamie Munro, global practice leader, portfolio and licensing, both of Clarivate Analytics, was to generate value from deals in the face of rising costs for drug development, pushback on pricing and a shift in focus from M&A to other types of business development (BD). Read More

Lilly's $8B buyout brings cancer pipeline, Vitrakvi aboard

Eli Lilly and Co. CEO Dave Ricks called the $8 billion buyout of Loxo Oncology Inc. "completely in line with what we've been talking about all along," although it's a deal "bigger than we've done before. In this case, you have four either clinical or recently approved medicines in one package, which is a bit unique for us." The bundle comes with a platform that may prove more broadly useful, he pointed out during a conference call with investors. Read More

Depression drug developers Axsome and Sage hit primary endpoints, stocks climb

Favorable phase II data with N-methyl-D-aspartate (NMDA) receptor antagonist AXS-05 sent Axsome Therapeutics Inc.'s shares skyrocketing more than 200 percent on Monday, and offered new hope for an estimated 16 million major depressive disorder (MDD) patients in the U.S. Read More

Apic Bio secures $40M to fund silence & replace gene therapy

Gene therapy has come a long way since the initial treatments of the early 1990s, but the insertion of genes can't help diseases with toxic gain-of-function mutations. Apic Bio Inc. is looking to overcome that limitation with its gene therapy platform, Thrive, which includes a second component expressing an miRNA to silence toxic gain-of-function mutations from a single vector. Read More

Celgene and BMS envision prosperous future in JPM opener

SAN FRANCISCO – For what J.P. Morgan analyst Cory Kasimov called "one of the most significant pre-conference announcements ever," the tradition-steeped J.P. Morgan Healthcare Conference broke form, just a little, turning an anticipated slide talk into a comfy fireside chat with Celgene Chairman and CEO Mark Alles and the chairman and CEO of Celgene acquirer Bristol-Myers Squibb Co., Giovanni Caforio, on Monday. With the typical Q&A session to follow canceled, runners poised to bolt from the back of the Westin St. Francis Hotel's Grand Ballroom sighed, just a little. Read More

Regeneron, Sanofi tidy I-O deal with payout and renewed focus

SAN FRANCISCO - A restructured global immuno-oncology deal between Regeneron Pharmaceuticals Inc. and Sanofi SA means "we're now pretty much in control of our entire pipeline of oncology agents," Regeneron's founder and CEO, Len Schleifer, told attendees at the J.P. Morgan Healthcare Conference on Monday. (See BioWorld, Oct. 2, 2018.) Read More

SCOTUS mulls drug company responsibility when FDA says no to label change

Should a jury second-guess the FDA's decisions in rejecting changes to prescription drug labeling? And just how much proof is needed to establish "clear evidence" that the FDA would have rejected a new warning for a drug label? Read More

AI firm Exscientia draws Roche to partnering table, adds $26M in series B

LONDON – It was double delight for Exscientia Ltd., as the artificial intelligence (AI) specialist sealed a CHF67 million (US$68.3 million) drug discovery deal with Roche Holding AG and announced the closing of a $26 million series B round. Read More

Immunic gains Nasdaq listing by reverse merger with Vital

DUBLIN – On the basis that 11 percent of something is better than 100 percent of nothing, Vital Therapies Inc., is throwing in its lot with privately held German drug development firm Immunic AG in a reverse merger that is being encouraged with an additional investment of €26 million (US$29.7 million) from Immunic's shareholders. The deal will transform Planegg-Martinsried-based Immunic into a Nasdaq-listed company, and it is embracing its new identity by moving its headquarters from the Munich region to Boston. Read More

Samsung Bioepis expands to China with 3Sbio deal

HONG KONG – South Korean biotech company Samsung Bioepis Co. Ltd. has entered a licensing agreement with China's 3Sbio Inc. to expand its biosimilars business to mainland China. The agreement covers multiple biosimilar candidates from the Incheon-based Samsung Bioepis, including SB-8, a biosimilar to blockbuster anti-VEGF antibody Avastin (bevacizumab, Genentech Inc./Roche Holding AG) that is undergoing phase III trials. Read More

PTO: Some exceptions need no inventiveness review if integrated

The U.S. Patent and Trademark Office (PTO) said its examiners will review patent applications that include a judicial exception to eligibility by examining whether that exception "is integrated into a practical application" of that exception. An application that passes this test will not be reviewed to determine whether the exception embodies an inventive concept, a policy that should at the very least provide more predictability to patent holders in the life sciences. Read More

Financings

Stelexis Therapeutics LLC, of New York, said it closed a $43 million series A financing. The company's drug discovery platform identifies the earliest definable pre-cancerous stem and progenitor cells that lead to the formation of human primary and recurrent tumors for therapeutic intervention and relapse prevention. The funding will support the delivery of clinical trial data and the validation of its platform. Read More

Regulatory front

The U.S. Supreme Court Monday declined to hear Gilead Sciences Inc. v. U.S., Ex Rel. Campie. The decision to deny cert is the end of the road for the whistleblower case, and it leaves standing a Ninth Circuit decision that the government's continued approval and payment for products after learning of alleged regulatory infractions doesn't foreclose False Claims Act allegations.  Read More

Other news to note

4D Pharma plc, of Leeds, U.K., and the University of Texas MD Anderson Cancer Center inked a collaboration to evaluate 4D's Live Biotherapeutic oncology pipeline across a range of cancer settings. The deal initially will assess lead candidate MRx-0518 as a potential treatment for solid tumors. Financial terms were not disclosed. Read More

Clinical data for Jan. 7, 2019

Read More

Regulatory actions for Jan. 7, 2019

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe